Yazar "Bulur, Şule" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Eritropoetinin Santral Sinir Sistemindeki Nöroprotektif Etkileri(2012) Bulur, Şule; Dikici, Süber; Demir, Şerif; Ankaralı, SeyitErythropoietin (Epo) acts primarily to stimulate erythroid cell production by supporting the survival, proliferation and differentiation of erythroid progenitor cells but It is now widely known that erythropoietin does not only affect the haematopoietic system. Erythropoietin has a dominant role for neuroprotection, neurogenesis, and acting as a neurotrophic factor in the central nervous system. A wide variety of experimental studies have shown that Epo and its receptor are expressed in the nervous system also Epo exerts remarkable neuroprotection in cell culture and animal models of nervous system disorders. The discovery that erythropoietin exerts neuroprotective properties has opened new therapeutic avenues. In this review, we summarize the current knowledge on the neuroprotective properties of Epo.Öğe Eritropoetinin Santral Sinir Sistemindeki Nöroprotektif Etkileri(2012) Bulur, Şule; Dikici, Süber; Demir, Şerif; Ankaralı, SeyitEritropoietin (Epo), esas olarak eritroid progenitör hücrelerin proliferasyonu, farklılaşması ve devamlılığını destekleyerek eritroid hücre üretimini uyarır. Ancak Eponun sadece hematopoetik sistemde etki etmediği artık yaygın olarak bilinmektedir. Eritropoetin santral sinir sisteminde nöroprotektif etkili, nörogenezde baskın bir role sahip ve nörotrofik bir faktör olarak etki göstermektedir. Çok çeşitli deneysel çalışmalar Epo ve reseptörünün sinir sisteminde varlığını ortaya koymuştur. Ayrıca Epo, hücre kültürü ve sinir sistemi bozukluklarının oluşturulduğu hayvan modellerinde belirgin nöroprotektif etki göstermektedir. Eritropoetinin nöroprotektif etkisinin keşfi yeni tedavi yollarının açığa çıkmasını sağlamıştır. Biz bu derlemede, Eponun mevcut nöroprotektif özellikleri hakkındaki bilgileri özetlemekteyiz.Öğe The Relationship Between Mean Platelet Volume with Metabolic Syndrome in Obese Individuals(LIPPINCOTT WILLIAMS & WILKINS, 2012) Kutlucan, Ali; Bulur, Serkan; Kır, Seher; Bulur, Şule; Önder, Elif; Aslantaş, Yusuf; Ekinözu, İsmail; Aydın, Yusuf; Özhan, HakanThe metabolic syndrome is closely associated with atherosclerotic risk factors and increased mortality. Mean platelet volume (MPV) is an indicator of platelet activation which also shows a close relationship with cardiovascular risk factors, such as diabetes mellitus, hypertension, hypercholesterolemia, obesity, metabolic syndrome. The aim of this study was to investigate the correlates of metabolic syndrome, its components and MPV adjusted for obesity in a large population study. A total of 2298 individuals with a mean age of 50 (age range 18-92) were interviewed. Nine hundred and twenty obese participants, who had BMI 30 kg/m(2) or more, further evaluated for the presence of metabolic syndrome. Five hundred and thirteen [396 women (70.2%)] had metabolic syndrome and the rest 407 individuals [324 women (79.6%)] served as the control group. The BMI, SBP, DBP, waist circumference, fasting plasma glucose, visceral fat, total cholesterol, high-density lipoprotein-cholesterol, and triglyceride was higher significantly in metabolic syndrome group (P=0.002 for BMI and P<0.001 for the others). No significant difference was observed between groups regarding low-density lipoprotein cholesterol, white blood cells, platelet counts, MPV, hematocrit and hemoglobin (P>0.05 for all). The presence of metabolic syndrome and its components do not constitute a difference in MPV values in obese patients with a BMI 30 kg/m(2) or more.
